Oncotarget Advocates for a Healthy Living through Insightful Scientific Publications
Oncotarget is a weekly based open access medical journal focusing on almost all the topics of oncology. It was first established in 2010 under the publications of Impact Journals, with Mikhail Blagosklonny as the editor-in-chief and Andrei Gudkov as his assistant. Oncotarget encompasses all the pathways, molecules and cell functions common during aging, cancer, neurodegeneration, and microbes. It is also common in lymphocytes, neurons, and atherosclerosis. The success of Oncotarget encouraged the publishers to launch more sections beyond oncology. Consequently, what was developed was a multi-disciplinary traditional journal with free access and can be printed for particular demands.
Benefits of the Oncotarget Publishers
The primary target of the publication includes:
Cancer Management and Research
Cancer research has been optimized and taken to another level through this open access, and peer reviewed journal. Oncotarget has a mission of ensuring a life free from disease. All the preventive and integrated treatment options and interventions have been explored and given proof-test, with an effort to achieve the intended outcomes which are to:
Enhance patient survival beyond infection.
Improve the quality of life of the people living with cancer and the patients.
Future of Oncotarget in the Medical field
Oncotarget seeks to chart a future where it will remain the international peer-reviewed journal. It will solely focus on pathological cancers, the therapy targets and treatment protocols as well as the management of cancer patients. The publication has been credited with enhancing and encouraging the change in perspectives such as the quality of life, satisfaction, and adherence to quality food and medication regimes. The journal will contribute substantially to discover new therapies and redefine their usage regarding uptake and acceptance by the patients and care professionals.